Roche Holding (RHHBY)
(Delayed Data from OTC)
$33.48 USD
+0.44 (1.33%)
Updated Jun 6, 2024 03:59 PM ET
4-Sell of 5 4
C Value C Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RHHBY 33.48 +0.44(1.33%)
Will RHHBY be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for RHHBY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RHHBY
The Zacks Analyst Blog Highlights Roche, Wells Fargo, General Aerospace and Key Tronic
Top Analyst Reports for Roche, Wells Fargo & GE Aerospace
RHHBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
Other News for RHHBY
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
Novartis, Roche facing Italy antitrust probe over Lucentis biosimilar
Deutsche Numis Keeps Their Hold Rating on Roche Holding AG (RHHVF)
Roche Holding AG (RHHVF) Receives a Sell from Goldman Sachs
Gilead, Arcus combo significantly reduces death risk in colorectal cancer